GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (FRA:5GH) » Definitions » Price-to-Free-Cash-Flow

Guardant Health (FRA:5GH) Price-to-Free-Cash-Flow : N/A (As of Jun. 10, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Guardant Health Price-to-Free-Cash-Flow?

As of today (2024-06-10), Guardant Health's share price is €26.56. Guardant Health's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €-2.41. Hence, Guardant Health's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Guardant Health's Price-to-Free-Cash-Flow or its related term are showing as below:

FRA:5GH's Price-to-Free-Cash-Flow is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 25.75
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Guardant Health's Free Cash Flow per Share for the three months ended in Mar. 2024 was €-0.28. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €-2.41.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -24.00% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -16.90% per year.

During the past 8 years, Guardant Health's highest 3-Year average Free Cash Flow per Share Growth Rate was 2.60% per year. The lowest was -71.20% per year. And the median was -12.10% per year.


Guardant Health Price-to-Free-Cash-Flow Historical Data

The historical data trend for Guardant Health's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health Price-to-Free-Cash-Flow Chart

Guardant Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial - - - - -

Guardant Health Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Guardant Health's Price-to-Free-Cash-Flow

For the Diagnostics & Research subindustry, Guardant Health's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Guardant Health's Price-to-Free-Cash-Flow Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Guardant Health's Price-to-Free-Cash-Flow falls into.



Guardant Health Price-to-Free-Cash-Flow Calculation

Guardant Health's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=26.56/-2.412
=N/A

Guardant Health's Share Price of today is €26.56.
Guardant Health's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.41.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Guardant Health  (FRA:5GH) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Guardant Health Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Guardant Health's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Guardant Health (FRA:5GH) Business Description

Traded in Other Exchanges
Address
3100 Hanover Street, Palo Alto, CA, USA, 94304
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Guardant Health (FRA:5GH) Headlines

No Headlines